Microcap Ledger Shattuck Labs, Inc. $STTK
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Austin, TX
- Fiscal year end
- December 31
- Shares outstanding
- 100,363,253 [10-Q 2026-08-11]
What the company doesAI summary of filing
Shattuck Labs is a clinical-stage biotechnology company developing monoclonal and bispecific antibodies targeting the DR3/TL1A pathway for inflammatory and immune-mediated diseases. The company's lead product candidate, SL-325, is a DR3 blocking monoclonal antibody currently in Phase 1 clinical trials in healthy volunteers, with Phase 2 trials in Crohn's disease patients planned for the third quarter of 2026. The company is also developing SL-425, a half-life extended version of SL-325, and multiple preclinical DR3-based bispecific antibodies. Shattuck Labs is pre-revenue and does not yet generate income from product sales. [10-K 2026-03-05]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$29.92M | −$23.61M | $63.30M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | $1.00M | −$48.81M | −$39.88M | $54.19M | [10-K 2026-03-05] |
| FY ended Dec 2024 | $5.72M | −$75.41M | −$60.52M | $57.39M | [10-K 2026-03-05] |
- Quarterly cash burn
- −$11.80M
- Cash runway Estimate
- ~16.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-17 | 47,899,240 | [10-K 2025-03-27] |
| 2025-04-01 | 47,899,240 | [10-K/A 2025-05-01] |
| 2025-04-21 | 47,899,240 | [10-Q 2025-05-01] |
| 2025-08-07 | 47,903,215 | [10-Q 2025-08-14] |
| 2025-10-23 | 63,279,843 | [10-Q 2025-11-06] |
| 2026-02-26 | 71,564,217 | [10-K 2026-03-05] |
| 2026-04-30 | 76,680,517 | [10-Q 2026-05-07] |
| 2026-08-07 | 100,363,253 | [10-Q 2026-08-11] |
- Shelf registration
- S-3 filed 2026-01-13; declared effective 2026-01-21 [S-3 2026-01-13]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-06 | Shukla Abhinav A. | exercise | 12,153 | $3.57 | [4 2026-07-07] |
| 2026-07-02 | Shukla Abhinav A. | exercise | 410 | $3.57 | [4 2026-07-07] |
| 2026-07-02 | Shukla Abhinav A. | sell | 410 | $7.01 | [4 2026-07-07] |
| 2026-07-01 | Shukla Abhinav A. | exercise | 100 | $3.57 | [4 2026-07-02] |
| 2026-07-01 | Shukla Abhinav A. | sell | 100 | $7.07 | [4 2026-07-02] |
| 2026-06-30 | Shukla Abhinav A. | exercise | 23,365 | $3.57 | [4 2026-07-02] |
| 2026-06-30 | Shukla Abhinav A. | sell | 23,365 | $7.08 | [4 2026-07-02] |
| 2026-06-30 | Pandite Arundathy N. | sell | 30,000 | $7.01 | [4 2026-07-02] |
| 2026-06-09 | Siegall Clay B | buy | 62,500 | $4.00 | [4 2026-06-11] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-11 | 8-K | Results of operations |
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-07-17 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-17 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-15 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-11 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-11 | 8-K | Material agreement entered |
| 2026-06-11 | 424B5 | Prospectus or prospectus supplement |
| 2026-06-09 | 424B5 | Prospectus or prospectus supplement |
| 2026-06-09 | 8-K | Regulation FD disclosure; Other events |
| 2026-06-02 | 8-K | Director or officer change; Shareholder vote results |
Alerts for $STTK
Email me when Shattuck Labs, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.